Aether Industries Ltd
NSE:AETHER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aether Industries Ltd
NSE:AETHER
|
IN |
|
IFAN Financial Inc
OTC:IFAN
|
US |
|
Humacyte Inc
NASDAQ:HUMA
|
US |
|
Sunil Healthcare Ltd
BSE:537253
|
IN |
|
T
|
Telus International Cda Inc
NYSE:TIXT
|
CA |
|
Opthea Ltd
ASX:OPT
|
AU |
|
Gyldendal ASA
OSE:GYL
|
NO |
|
Beetaloo Energy Australia Ltd
ASX:BTL
|
AU |
|
T
|
TriState Capital Holdings Inc
F:3ZS
|
US |
|
D
|
Danang Housing Investment Development JSC
VN:NDN
|
VN |
|
Moody's Corp
NYSE:MCO
|
US |
Aether Industries Ltd
In the bustling landscape of India's chemical industry, Aether Industries Ltd. charts a path defined by innovation and precision. Founded on the vision of seamlessly marrying chemistry with technology, Aether has carved out a niche as a specialty chemicals manufacturer. The company focuses on high-value chemistries that cater to sectors like pharmaceuticals, agrochemicals, and material sciences. Leveraging a robust research and development framework, Aether crafts complex, multi-step synthesis processes that elevate their products above commodity chemicals. This innovation-focused approach allows them to serve global giants across diverse industries, fostering partnerships that bolster their reputation for quality and reliability.
What truly sets Aether Industries apart is its adeptness at generating significant value from its intellectual capital. Rather than merely churning out chemicals, Aether emphasizes offering bespoke solutions tailored to their clients' unique requirements. By investing heavily in their R&D capabilities, they continually push the boundaries of what's possible with chemical compounds. Their financial engine is fueled by a strategic blend of direct sales of specialty chemicals, licensing of proprietary technologies, and long-term supply agreements. This trifecta ensures a steady and resilient revenue stream, while their commitment to operational excellence and sustainability further strengthens their market position, making them a pivotal player in the specialty chemicals domain.
In the bustling landscape of India's chemical industry, Aether Industries Ltd. charts a path defined by innovation and precision. Founded on the vision of seamlessly marrying chemistry with technology, Aether has carved out a niche as a specialty chemicals manufacturer. The company focuses on high-value chemistries that cater to sectors like pharmaceuticals, agrochemicals, and material sciences. Leveraging a robust research and development framework, Aether crafts complex, multi-step synthesis processes that elevate their products above commodity chemicals. This innovation-focused approach allows them to serve global giants across diverse industries, fostering partnerships that bolster their reputation for quality and reliability.
What truly sets Aether Industries apart is its adeptness at generating significant value from its intellectual capital. Rather than merely churning out chemicals, Aether emphasizes offering bespoke solutions tailored to their clients' unique requirements. By investing heavily in their R&D capabilities, they continually push the boundaries of what's possible with chemical compounds. Their financial engine is fueled by a strategic blend of direct sales of specialty chemicals, licensing of proprietary technologies, and long-term supply agreements. This trifecta ensures a steady and resilient revenue stream, while their commitment to operational excellence and sustainability further strengthens their market position, making them a pivotal player in the specialty chemicals domain.
Strong Growth: Revenue rose 44% year-on-year in Q3 FY'26, with EBITDA up 75% and PAT up 49%, reflecting robust business momentum.
Business Mix Shift: Non-pharma and non-agro segments, especially oil & gas and material science, are gaining share and expected to grow further by year-end.
Expansion Progress: Construction and trial runs at new production sites (Site 3++ and Site 5) are complete; commercial production to start soon, adding capacity.
Margin Performance: Q3 EBITDA margin improved to 34% versus 28% last year, but management guides for a more conservative 29–30% going forward.
New Clients & Products: Five new marquee clients added this quarter; new product launches in large-scale manufacturing and expansion in CRAMS and CEM businesses.
R&D Investment: Significant ongoing and planned expansions in R&D capacity, targeting non-pharma/non-agro sectors with advanced labs and equipment.
Working Capital: Working capital days increased to 160 due to inventory build-up for new sites, but expected to normalize as production ramps up.
Strategic Contracts: Long-term, transparent contracts in place with international clients, especially in Europe, amid global chemical manufacturing shifts.
